The Scientist

» industry and microbiology

Most Recent

Post-publication peer review prompts the authors to clarify the ages of mice used in their experiments and share additional data.

0 Comments

image: Pfizer Scoops Anacor for $5.3 Billion

Pfizer Scoops Anacor for $5.3 Billion

By | May 17, 2016

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

0 Comments

image: Narrow-Spectrum Antibiotic Could Spare the Microbiome

Narrow-Spectrum Antibiotic Could Spare the Microbiome

By | May 9, 2016

A drug that singles out Staphylococcus aureus leaves gut-dwelling microbiota largely intact, a mouse study shows.

0 Comments

image: Most Gut Microbes Can Be Cultured

Most Gut Microbes Can Be Cultured

By | May 4, 2016

Contrary to the popular thought that many species are “unculturable,” the majority of bacteria known to populate the human gut can be grown in the lab, scientists show.

0 Comments

image: Earth: Home to 1 Trillion Microbial Species

Earth: Home to 1 Trillion Microbial Species

By | May 4, 2016

A new analysis of microbial data estimates that the world is home to 1 trillion species—of which only 0.001 percent have been discovered.

0 Comments

image: Becoming Acculturated

Becoming Acculturated

By | May 1, 2016

Techniques for deep dives into the microbial dark matter

0 Comments

image: Lu on Syn Bio

Lu on Syn Bio

By | May 1, 2016

MIT researcher and Scientist to Watch Timothy Lu talks about the value of cross-disciplinary approaches in bringing synthetic biology into the clinic.

0 Comments

image: Timothy Lu: Niche Perfect

Timothy Lu: Niche Perfect

By | May 1, 2016

Associate Professor, Departments of Electrical Engineering & Computer Science and Biological Engineering, MIT. Age: 35

0 Comments

image: Microbial Ice-Makers

Microbial Ice-Makers

By | April 26, 2016

How one bacterium turns water into ice at nonfreezing temperatures

4 Comments

image: Another Gene-Editing IPO

Another Gene-Editing IPO

By | April 12, 2016

Intellia Therapeutics, which seeks to develop CRISPR-based technologies to target rare diseases, is hoping to raise $120 million in an initial public offering.

0 Comments

Popular Now

  1. Neurons Compete to Form Memories
  2. Mapping the Human Connectome
    Daily News Mapping the Human Connectome

    A new map of human cortex combines data from multiple imaging modalities and comprises 180 distinct regions.

  3. The Genetic Components of Rare Diseases
  4. Classic Example of Symbiosis Revised
RayBiotech